Snapshot from Sep 20, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech clinical trial results

Teva Phase 2a Celiac Disease Trial Success

Analysis based on 11 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026

Sentiment
70
Attention
4
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Positive clinical data for TEV '408 could boost Teva's stock as it validates a key pipeline asset with potential in multiple indications. The results may also increase confidence in Teva's innovative drug strategy and its partnership with Royalty Pharma.

Pharmaceuticals Biotechnology

Sun Pharma announced positive topline results from its Phase 2a study of TEV '408, an investigational anti-IL-15 monoclonal antibody, in adults with celiac disease. The study met its primary endpoint, showing statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8. TEV '408 was well-tolerated with no safety signals observed. These results, combined with the vitiligo program, support TEV '408 as a potential pipeline-in-a-product opportunity. Teva plans to present further data at a future scientific meeting and will hold an investor call to discuss the results.

100 Sun Pharma announced positive results
60 Sun Pharma secured R&D funding Royalty Pharma
40 Sun Pharma received Fast Track designation United States — Food and Drug Administration
stock
Teva is the developer of TEV '408 and announced the positive Phase 2a results, which could significantly enhance its pipeline value and growth prospects.
Importance 100.0 Sentiment 80.0
stock
Royalty Pharma has a strategic funding agreement with Teva for TEV '408, and positive results may increase the potential value of its investment.
Importance 40.0 Sentiment 60.0
govactor
The FDA granted Fast Track designation to TEV '408 for celiac disease, which may expedite its development and review.
Importance 30.0 Sentiment 50.0
per
Eric Hughes, Teva's Chief Medical Officer, commented on the results, highlighting their significance for celiac disease treatment.
Importance 20.0 Sentiment 50.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.